{"id":8314,"date":"2020-07-17T15:12:02","date_gmt":"2020-07-17T22:12:02","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8314"},"modified":"2021-04-02T15:12:53","modified_gmt":"2021-04-02T22:12:53","slug":"hydroxychloroquine-in-nonhospitalized-adults-with-early-covid-19-a-randomized-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/07\/17\/hydroxychloroquine-in-nonhospitalized-adults-with-early-covid-19-a-randomized-trial\/","title":{"rendered":"Hydroxychloroquine in\u00a0Nonhospitalized\u00a0Adults\u00a0With\u00a0Early COVID-19: A Randomized Trial"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"46\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Skipper et al<\/span><span data-contrast=\"auto\">. report<\/span><span data-contrast=\"auto\">\u00a0findings of a randomized, double-blind placebo-controlled trial of oral hydroxychloroquine (800mg once, followed by 600mg in 6-8 hours, then 600mg daily for 4 days) among symptomatic non<\/span><span data-contrast=\"auto\">&#8211;<\/span><span data-contrast=\"auto\">hospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 (n=423).\u00a0<\/span><span data-contrast=\"auto\">Patients in the\u00a0<\/span><span data-contrast=\"auto\">hydroxychloroquine\u00a0<\/span><span data-contrast=\"auto\">arm had a non-significantly lower probability of ongoing symptoms at 14 days (24% versus 30%<\/span><span data-contrast=\"auto\">; p=<\/span><span data-contrast=\"auto\">0.21<\/span><span data-contrast=\"auto\">)<\/span><span data-contrast=\"auto\">.\u00a0<\/span><span data-contrast=\"auto\">There were 5 events of hospitalization and\/or death within 14 days among the hydroxychloroquine arm compared to 10 events in the placebo arm (p=0.29).<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"46\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"auto\">Risk<\/span><span data-contrast=\"auto\">\u00a0of medication-related adverse effects\u00a0<\/span><span data-contrast=\"auto\">was significantly higher in the\u00a0<\/span><span data-contrast=\"auto\">hydroxychloroquine\u00a0<\/span><span data-contrast=\"auto\">arm<\/span><span data-contrast=\"auto\">\u00a0(43% versus 22%<\/span><span data-contrast=\"auto\">), with gastrointestinal effects being\u00a0most commonly reported<\/span><span data-contrast=\"auto\">\u00a0and no\u00a0<\/span><span data-contrast=\"auto\">serious adverse events attributable to\u00a0<\/span><span data-contrast=\"auto\">hydroxychloroquine<\/span><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Skipper et al. (July 2020). Hydroxychloroquine in\u00a0Nonhospitalized\u00a0Adults\u00a0With\u00a0Early COVID-19: A Randomized Trial. Annals of Internal Medicine.\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.7326\/M20-4207\"><span data-contrast=\"none\">https:\/\/doi.org\/10.7326\/M20-4207<\/span><\/a><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Skipper et al. report\u00a0findings of a randomized, double-blind placebo-controlled trial of oral hydroxychloroquine (800mg once, followed by 600mg in 6-8 hours, then 600mg daily for 4 days) among symptomatic non&#8211;hospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 (n=423).\u00a0Patients in the\u00a0hydroxychloroquine\u00a0arm had a non-significantly lower probability of ongoing symptoms at 14 days (24% versus 30%; p=0.21).\u00a0There&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/07\/17\/hydroxychloroquine-in-nonhospitalized-adults-with-early-covid-19-a-randomized-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[19],"class_list":["post-8314","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8314"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8314\/revisions"}],"predecessor-version":[{"id":8315,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8314\/revisions\/8315"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8314"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}